Help Ensure Access to Paxlovid for COVID-19

July 2022

You play a key role in limiting treatment delays with Paxlovid (nirmatrelvir/ritonavir) for patients with COVID-19.

Help HIGH-risk patients start within the 5-day window.

Dispensing. Any type of positive COVID-19 test is enough to qualify for Paxlovid, even a home test. And the med is still no cost to patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote